Stay updated on Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page now includes an expanded Locations section with new study sites in Pordenone and Turin, updating where the trial is conducted. The footer item HHS Vulnerability Disclosure was removed (a minor change) and the revision updated to v3.3.3.SummaryDifference0.3%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no changes to core content or user-facing data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check31 days agoChange DetectedRevision: v3.3.1 is now shown on the page, replacing the previous Revision: v3.2.0.SummaryDifference0.1%

- Check39 days agoChange DetectedRemoved the government funding status notice banner that warned users about potential delays in updates and responses. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check53 days agoChange DetectedThe page content appears unchanged; there are no updates to study details between versions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check82 days agoChange DetectedAdded an important operating-status notice and a new version tag (v3.2.0); removed the old version tag (v3.1.0).SummaryDifference4%

Stay in the know with updates to Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.